Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > New ceo please
View:
Post by SleepyHoward on Feb 14, 2024 9:46am

New ceo please

Now that you become a professionell company please change the ceo to bring the trust back to the shareholders. 

That is the only way to get a better shareprize
Comment by biorun on Feb 14, 2024 10:35am
I would presume the Sirona Laboratories subsidiary would have a new CEO attached to that organization. So we wait to see what they come up with re equity raise, and then essentially: 1067: this is led by Allergan/AbbVie senior leadership 1326: this would be led by new Sirona Laboratories CEO Other pipelines under Sirona Laboratories - same So in essence, we may see more of the execution control ...more  
Comment by forhandlaren on Feb 14, 2024 1:08pm
I agree that a new CEO would be great, but it will not happen before sales cashflow has been established. Simply put - the company cannot afford it yet, but maybe in the autumn 2025. Therefore I hope that Sirona Laboratories will appoint someone who can deliver some real financial value. The upside with a financial partner will be requirements beyond the current CEO capabilities so a change is ...more  
Comment by Turtle4 on Feb 14, 2024 1:37pm
Don't shout too loudly for a new ceo. You know the company, they always manage to surprise in a negative way. In the end it will be someone who previously had PRC Partners on their CV...
Comment by biorun on Feb 14, 2024 2:32pm
If they don't have a budget item for at least 1-2 years of a CEO salary for Sirona Laboratories then they are not thinking straight. Any equity partner would very likely insist on seeing someone in the chair, and perhaps even participate on the selection.
Comment by forhandlaren on Feb 14, 2024 3:56pm
Perhaps I didn't make myself clear. The parent company will most likely not be able to afford a new CEO until autumn 2025. The subsidary Sirona Laboratories should be able to afford an operational leader of some flavour. It's in the best interest of the financial partner and the shareholders of the parent company.
Comment by tylerreddick on Feb 14, 2024 4:02pm
The AbbVie deal was supposed to solve all of our financial problems. Apparenty that was bs.
Comment by Transperance on Feb 15, 2024 1:46am
Tyler, We don’t know, so we can only speculate. My speculation is that the Abbvie 1067 Right of first refusal terms gave them an advantage in the deal negotiation. If I recall it correctly, Abbvie co-financed, or perhaps even financed, the clinical study and I think Sirona had to pay more than expected for that financing later on in the 1067 deal terms. Looking forward, there are no such Right ...more  
Comment by tylerreddick on Feb 15, 2024 7:50am
" I think this was a lesson learned. " If Howie is still learning lessons, he needs to be gone.
Comment by lscfa on Feb 15, 2024 7:52am
Shareholders are paying for mgmt's expensive education while they attend keggers and play beer pong.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities